European Heart Journal · 2023 · 10 citations · 8 references
MedicineCardiologyPharmacotherapyCardiovascular PharmacotherapyPreventive CardiologyWomen's HealthCardiac MedicationsCardiovascular DiseaseHeart FailureHeart Failure PharmacotherapyHeart Failure EpidemiologyHeart Failure Hemodynamic EvaluationHemodynamic CharacteristicsHemodynamic PhenotypingLeft Ventricular Ejection Fraction DeclineSex Differences In CardiomyopathySex Differences In MorbiditySex-specific Epidemiology
Sex-differences in characteristics and outcome in heart failure with preserved ejection fraction (HFpEF) have been well documented.1,2 However, whether these differences vary by left ventricular ejection fraction (LVEF) are unclear. A recent study showed substantial differences in morphological and hemodynamic characteristics in HFpEF patients with high-normal (>60%) vs. low-normal (50%–60%) LVEF, which might partly explain their heterogeneous responses to pharmacotherapy.3 Post-hoc analyses of clinical trials suggest that the benefits of neurohormonal modulators extended to a higher range of LVEF in women than in men.4,5 It is therefore important to compare clinical characteristics and outcomes between male and female HFpEF patients by LVEF. Additionally, recent epidemiologic studies reported a new phenotype characterized by supranormal LVEF (LVsnEF);6,7 whether there are sex differences in LVsnEF deserves further investigation. The China Cardiovascular Association (CCA) Database-Heart Failure (HF) Center Registry is a nationwide multicentre study, which was approved by the Central Ethics Committee of Beijing Hospital (2018BJYYEC-059-02).8 All secondary and tertiary hospitals from mainland China are welcome to participate in the registry, and no additional specific selection criteria are required. Between January 2017 and December 2021, 575 CCA Database-HF Center-certified secondary and tertiary hospitals across the 31 provinces of mainland China participated in the registry. Hospitalized patients with a principal discharge diagnosis of HF were eligible for the registry, and those who died during index hospitalization were excluded. Diagnostic criteria of HF are based on the guidelines,9,10 including presence of clinical symptoms/signs of HF, cardiac structural and/or functional abnormality on echocardiogram, and elevated serum natriuretic peptide level. If LVEF was ≥50% as measured by echocardiography at index hospitalization, HF was defined as HFpEF.9,10 Among the overall HFpEF patients recruited (n = 125 208), after excluding those who were lost to follow-up (n = 8321), had <1-year of follow-up after discharge (n = 65 151), or lacked sex data (n = 25), 51 711 hospitalized HFpEF patients were included. Data from electronic and/or physical health records were collected and entered into an online central database by trained staff. Study variables collected included demographics, anthropometrics, education, vital signs at admission, HF characteristics [precipitating factors for index HF admission, hospitalization for HF (HHF) in the previous 12 months, clinical symptoms/signs, New York Heart Association (NYHA) class], laboratory and echocardiography data, comorbidities [smoking status, alcohol consumption, hypertension, diabetes mellitus, dyslipidaemia, obesity, chronic kidney disease (CKD), atrial fibrillation (AF), coronary heart disease (CHD), prior myocardial infarction, prior stroke/transient ischaemic attack, peripheral arterial disease, chronic obstructive pulmonary disease (COPD), anaemia, thyroid dysfunction, obstructive sleep apnoea, anxiety/depression, and cancer], prior intervention and device therapy, and medications prescribed at discharge. After discharge, patients were followed by trained physicians during an outpatient visit or via a telephone interview during the first week (±1 week), the first month (±14 days), the third month (±30 days), and the first year (±90 days). The primary outcome was a composite of HHF or cardiovascular death. Follow-up duration was calculated from the date of discharge until the occurrence of the first event (HHF or cardiovascular death) or at the end of 1-year follow-up if no event occurred. All-cause death and all-cause hospitalization were evaluated as secondary outcomes. All events were reported by the participants or their immediate relatives without adjudication. Patients were divided into three groups based on LVEF (50%–59%, 60%–69%, and ≥70%), and LVEF ≥70% was defined as LVsnEF.7 Baseline characteristics between men and women across the three groups were compared using the Student’s t-test, Mann–Whitney U test, or Chi-squared test as appropriate. Cox proportional hazard models were used to evaluate the association between sex and outcomes across the three groups, with men serving as the reference group. Covariates [age, education, systolic blood pressure, precipitating factor for index HF admission, HHF in the previous 12 months, NYHA class, estimated glomerular filtration rate (eGFR), LogN-terminal pro-brain natriuretic peptide (NT-proBNP), haemoglobin concentration, smoking status, hypertension, diabetes mellitus, obesity, AF, CHD, prior myocardial infarction, COPD, thyroid dysfunction, depression/anxiety, and prior percutaneous coronary intervention] and medications prescribed at discharge were incorporated in the model. To assess whether the association between sex and outcomes varied by LVEF, we included a sex-by-LVEF multiplicative interaction term in the model. Hazard ratio (HR), 95% confidence interval (CI), and P-interaction were reported. A two-sided P-value < .05 was considered statistically significant. All analyses were performed using Stata 15.1 (Stata Corp LLC, College Station, TX, USA) and R (version 4.1.2; The R Foundation for Statistical Computing, Vienna, Austria). The percentage of HFpEF patients in each of the three LVEF groups as separated by sex is shown in Figure 1A. Sex differences in clinical characteristics presented a similar pattern across the three LVEF groups. Compared with men, women were older, more symptomatic, more likely to have NYHA class III/IV, had lower eGFR, and higher NT-proBNP levels. Women were more likely to have hypertension, AF, CKD, and thyroid dysfunction, and men were more likely to have CHD, prior myocardial infarction, and COPD. Women were more likely to receive mineralocorticoid receptor antagonist, diuretic, and digitalis at discharge. Sex-specific clinical characteristics and 1-year outcomes across the three LVEF groups. Panel A: Percentage of HFpEF patients across the three LVEF groups in men and women. Panel B: Cumulative incidence of the composite primary outcome and its components, all-cause death and all-cause hospitalization at 1-year follow-up in men and women. Panel C: Associations between sex and the composite primary outcome and its components, all-cause death, and all-cause hospitalization using Cox proportional regression analyses. A sex-by-LVEF multiplicative interaction term was added in the regression analyses. In the model, baseline covariates (age, education, systolic blood pressure, precipitating factor for index HF admission, HHF in previous 12 months, NYHA class, eGFR, logNT-proBNP, haemoglobin concentration, smoking status, hypertension, diabetes mellitus, obesity, AF, CHD, prior myocardial infarction, COPD, thyroid dysfunction, depression/anxiety, and prior percutaneous coronary intervention) and medications prescribed at discharge were incorporated. AF, atrial fibrillation; CKD, chronic kidney disease; NYHA, New York Heart Association; NT-proBNP, N-terminal pro-brain natriuretic peptide; MRA, mineralocorticoid receptor antagonist; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; SGLT2i, sodium-glucose cotransporter 2 inhibitor; LVEF, left ventricular ejection fraction; HHF, hospitalization for heart failure; CV, cardiovascular; HR, hazard ratio; CI, confidence interval. Cumulative incidences of the composite primary outcome and its components, all-cause death and all-cause hospitalization at 1-year follow-up in men and women across the three LVEF groups are shown in Figure 1B. After adjustment for covariates (Figure 1C), female sex remained independently associated with higher risks for the composite primary outcome [HR 1.07 (95% CI 1.02–1.12)], HHF [HR 1.06 (95% CI 1.01–1.12)], all-cause death [HR 1.16 (95% CI 1.08–1.24)], and all-cause hospitalization [HR 1.05 (95% CI 1.01–1.09)], and there was no significant sex-by-LVEF interaction on outcomes (P-interaction >.05 for all). Among hospitalized HFpEF patients, the pattern of differences between sexes in clinical characteristics did not vary by LVEF, and women generally had worse clinical profiles. Women had higher adjusted risks for adverse outcomes at 1-year follow-up, and the association between sex and outcomes did not vary by LVEF. There were slight sex differences in LVsnEF. Study limitations include the possibility of residual confounding, lack of data on management during index admission and at follow-up, and events were not adjudicated. We appreciate very much the contributions made by the Heart Failure Center Alliance and China Heart House in the construction of the Heart Failure Center. Thanks to all participating hospitals and colleagues. Thanks to all the experts of the expert committee of the Heart Failure Center (https://www.chinahfc.org/index.php?c=category&id=7) and all of the Heart Failure Center certification unit (https://www.chinahfc.org/index.php?c=category&id=98). Supplementary data are not available at European Heart Journal online. The authors declare that they do not have any conflicts of interest to disclose. The data underlying this article cannot be shared publicly considering the privacy of individuals who participated in the study. The data and underlying code can be shared on reasonable request to the corresponding author. All authors declare no funding for this contribution. This study was approved by the Central Ethics Committee of Beijing Hospital (2018BJYYEC-059-02). Not applicable.
8
John G.F. Cleland, Andrew J.S. Coats, Ewa A. Jankowska et al. · PubMed · 2021 · 19.5K citations
[Chinese guidelines for the diagnosis and treatment of heart failure 2014].
PubMed · 2014 · 368 citations